摘要
目的:探讨重症急性胰腺炎(SAP)患者血清可溶性白细胞分化抗原14亚型(sCD14-st)、微管相关蛋白1轻链3(MAP1-LC3)、白细胞介素-18(IL-18)水平变化对疗效的评估价值。方法:回顾性选取2022年1月-2024年10月本院收治的64例SAP患者作为研究组,选取同期轻症急性胰腺炎64例作为对照组。比较2组血清sCD14-st、MAP1-LC3、IL-18水平与急性生理学与慢性健康状况评分系统I(APACHE-II)、急性胰腺炎CT严重程度指数(CTSI),分析血清sCD14-st、MAP1-LC3、IL-18与APACHE-I、CTSI评分相关性。依据治疗14d后临床疗效分为2个亚组:有效亚组46例、无效亚组18例,比较其血清sCD14-st、MAP1-LC3、IL-18水平,评价血清sCD14-st、MAP1-LC3、IL-18水平对疗效的评估价值。结果:研究组血清sCD14-st、MAP1-LC3、IL-18水平高于对照组(P<0.05);血清sCD14-st、MAP1-LC3、IL-18与APACHE-IⅡI(r=0.428、0.388、0.502,P=0.018、0.029、0.008)、CTSI评分呈正相关(r=0.463、0.407、0.477,P=0.013、0.021、0.011);无效亚组治疗1d后、治疗3d后血清sCD14-st、MAP1-LC3、IL-18水平高于有效亚组(P<0.05);血清sCD14-st、MAP1-LC3、IL-18联合评估疗效的AUC值大于单项指标评估(P<0.05)。结论:SAP患者血清sCD14-st、MAP1-LC3、IL-18水平与病情严重程度呈正相关,动态检测其水平对疗效具有一定评估价值,联合检测其水平可提高评估效能。
Objective:To evaluate the therapeutic effect of serum soluble leukocyte diferentiation antigen 14 subtype(sCD14-st),microtubule-associated protein 1 light chain 3(MAP1-LC3)and interleukin-18(IL-18)in patients with severe acute pancreatitis(SAP).Methods:Sixty-four SAP patients admitted to our hospital from January 2022 to October 2024 were retrospectively selected as the study group,and 64 cases of mild acute pancreatitis during the same period were selected as the control group.Serum sCD14-st,MAP1-LC3,and IL-18 levels were compared between the 2 groups with the Acute Physiology and Chronic Health Status Scoring System II(APACHE-I)and the CT Severity Index(CTSI)for acute pancreatitis.Serum sCD14-st,MAP1-LC3,and IL-18 were analyzed for correlation with APACHE-II and CTSI scores.Based on the clinical efficacy after 14 d of treatment,they were divided into 2 subgroups:46 cases in the effective subgroup and 18 cases in the ineffective subgroup,and their serum sCD14-st,MAP1-LC3,and IL-18 levels were compared.The value of serum sCD14-st,MAP1-LC3,and IL-18 levels in evaluating the therapeutic efficacy was evaluated.Results:The serum levels of sCD14-st,MAP1-LC3 and IL-18 in the study group were higher than those in the control group(P<0.05).Serum sCD14-st,MAP1-LC3 and IL-18 were positively correlated with APACHE-II(r-0.428,0.388,0.502,P=0.018,0.029,0.008)and CTSI scores(r-0.463,0.407,0.477,P=0.013,0.021,0.011).Serum levels of sCD14-st,MAP1-LC3 and IL-18 in the ineffective subgroup were higher than those in the effective subgroup after 1 day and 3 days of treatment(P<0.05).The AUC value of the combined assessment of serum sCD14-st,MAP1-LC3,and IL-18 for eficacy evaluation is greater than that of single indicators.Conclusion:The levels of serum sCD14-st,MAP1-LC3,and IL-18 in SAP patients were positively correlated with the severity of the disease,and the dynamic detection of their levels has a certain value for the assessment of the efficacy of the treatment,and the combined detection of their levels can improve the assessment ofthe efficacy.
作者
刘云飞
张欣欣
王宣博
LIU Yun-fei;ZHANG Xin-xin;WANG Xuan-bo(Shangqiu Municipal Hospital of Traditional Chinese Medicine,Henan Shangqiu 476000)
出处
《医学检验与临床》
2025年第4期34-37,76,共5页
Medical Laboratory Science and Clinics
关键词
重症急性胰腺炎
可溶性白细胞分化抗原14亚型
微管相关蛋白1轻链3
白细胞介素-18
疗效
Severe acute pancreatitis
Soluble leukocyte differentiation antigen 14 subtype
Microtubule-associated protein 1 light chain 3
Interleukin-18
Curative effect
